ARGX Dec 2024 380.000 put
| Previous close | 2.5500 |
| Open | 2.5500 |
| Bid | 0.0000 |
| Ask | 5.0000 |
| Strike | 380.00 |
| Expiry date | 2024-12-20 |
| Day's range | 2.5500 - 2.5500 |
| Contract range | N/A |
| Volume | |
| Open interest | 13 |
- Yahoo Finance Video
Amgen stock falls on lackluster drug data
Shares of Amgen (AMGN) are sliding after the biotech company posted disappointing results from two drug studies. Market Domination Hosts Julie Hyman and Josh Lipton break down the updates from Amgen's immunology and rare disease development pipeline and discuss how the drugmaker is stacking up to its competitors. For more expert insight and the latest market action, click here to watch this full episode of Market Domination. This post was written by Melanie Riehl
Investor's Business DailyArgenx Stock Surges As Amgen Struggles To Take On 'The King' In Autoimmune Diseases
Argenx stock surged Wednesday after Amgen presented "underwhelming" results for a potential competitor to Vyvgart in an autoimmune disease.
GlobeNewswireargenx Announces Publication in The Lancet Neurology of Pivotal ADHERE Study Data in Chronic Inflammatory Demyelinating Polyneuropathy
ADHERE was largest and most innovative clinical trial of CIDP patients to date VYVGART® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) demonstrated reduction in disease progression, reduced risk of relapse and rapid onset of action VYVGART Hytrulo is first and only neonatal Fc receptor (FcRn) blocker FDA-approved to treat CIDP September 19, 2024 – 7:00 am CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of peop
